| Title: |
P0255 Effectiveness and safety of recombinant herpes zoster vaccination in ibd patients: a multicenter prospective study |
| Authors: |
Castiglione, F; Guarino, A D; Pinchera, B; Spadaro, G; Zappulo, E; Calabrese, G; Rispo, A; Testa, A; Nardone, O M; Mucherino, C; Miranda, A; Vespere, G; Imperatore, N; Capone, P; Patturelli, M; Gravina, A G; Pellegrini, L; Gentile, I |
| Source: |
Journal of Crohn’s and Colitis ; volume 20, issue Supplement_1 ; ISSN 1873-9946 1876-4479 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2026 |
| Description: |
Background Patients with inflammatory bowel disease(IBD)have a higher risk of varicella zoster virus infection (VZI) than the general population, largely due to immunosuppressive-biologic therapies. Preventing viral reactivation is a relevant clinical goal. The recombinant zoster vaccine (RZV, Shingrix) has shown high efficacy and good tolerability in the general population,but data in IBD are limited. Real-world evidence on its effectiveness and safety is needed to support vaccination strategies and guide clinical practice. The objective of the study was to assess the effectiveness and safety of the RZV in IBD. Methods From March 2023 to September 2024, consecutive IBDpatients who received the RZV Shingrix before starting or with ongoing biologics were prospectively enrolled across 9 tertiary IBDcenters. Effectiveness was assessed clinically and defined as the absence of VZI or HZ reactivation during the observation period. Safety outcomes included the occurrence of vaccine-related adverse events (AEs)—such as fever, arthralgia, and others—systematically recorded during the follow-up after each vaccine dose. Results A total of 420 IBD cases were included, comprising 215 (51.2%) with UC and 205 (48.8%) with CD. Most patients (95.8%) completed the VZV vaccination cycle. Biologic therapy was ongoing in 319 (75.9%) patients, more frequently in CD than UC (p < 0.001). During a mean follow-up of 11.0 ± 1.2 months, VZV reactivation occurred in only 0.7% of patients, confirming a high clinical effectiveness of RZV in IBD. Overall, AEs were reported in 52.4% of cases, with the most common being arm pain (37.1%), followed by asthenia (16.0%) and fever (13.8%). No significant differences between UC and CD (54.4% vs 50.2%, p = 0.448), as for gender (p = 0.96), were found. AE occurrence was significantly associated with ongoing biologic therapy (56.9% vs 29.3% without, p = 0.009) and lower age (median 42 vs 45.5 years, p = 0.047). However, analyzing therapies by specific mechanism of action, no class of drug ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ecco-jcc/jjaf231.436 |
| Availability: |
https://doi.org/10.1093/ecco-jcc/jjaf231.436; https://academic.oup.com/ecco-jcc/article-pdf/20/Supplement_1/jjaf231.436/66499785/jjaf231.436.pdf |
| Rights: |
https://academic.oup.com/pages/standard-publication-reuse-rights |
| Accession Number: |
edsbas.A40FDE5 |
| Database: |
BASE |